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Background: Pancreas surgery has evolved with better diagnostic imaging, changing indications, and
improved patient selection. Outside high-volume tertiary centers, the documented effect of evolution in
care and volumes are limited. Thus, we aimed to review indications and outcomes in pancreas surgery
during the transition from community-based hospital to a university hospital.
Methods: All pancreatic surgeries performed between 1986 and 2012 within a well-deﬁned Norwegian
population were identiﬁed from the hospital's database. Indications and postoperative outcomes,
including mortality, were investigated.
Results: Of the 219 included patients (54% males; median age, 64 years), 150 (69%) underwent pan-
creatoduodenectomy; 55 (25%), distal resection; and 5 (2%), enucleation. The annual number of opera-
tions increased during the study period (from <10/yr to >20/yr). Most patients (169; 77%) underwent
surgery for suspected malignancy. The 30-day mortality decreased signiﬁcantly over time among pa-
tients treated for pancreatic cancer (from 16.1% to 3.5%; p ¼ 0.012). Over time, signiﬁcant reductions in
median hospitalization time (19 versus 12 days; p < 0.001), re-operation rate (37.1% versus 8.4%;
p < 0.001), and median ICU stay (3 versus 0 days; p < 0.001) were observed.
Conclusion: The transition to university hospital and increase in volume has led to signiﬁcant im-
provements in several performance metrics and reduced postoperative mortality. We believe improved
perioperative management and focused, multidisciplinary care-bundles to be of importance.
Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic surgery has undergone substantial changes over the
last several decades and are now considered safe, albeit chal-
lenging, operations [1,2]. Recently, more attention has been paid to) at the A-EHPBA Congress in
testinal Surgery, Stavanger
orway.
de).
blishing Group Ltd. This is an openthe postoperative outcomes of complex elective gastrointestinal
surgery, and differences in outcomes between so called “low-vol-
ume” and “high-volume” hospitals have stimulated debate on the
centralization of these operations [3e5]. Many assertions have
been made in this debate; however, there are no ﬁrm conclusions
regarding what constitutes “low-volume” versus “high-volume”,
and the outcome criteria, patient referral bias, hospital case mix,
and other confounding factors have not been deﬁned [6e13].
Notably, favorable outcomes after pancreas surgery have been re-
ported at lower volume centers [10,14e16]. Hence, numerous
additional factors, such as a multidisciplinary approach thataccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
J.A. Søreide et al. / International Journal of Surgery 32 (2016) 116e122 117includes contrast-enhanced CT imaging, around-the-clock inter-
ventional radiology, multimodal oncology, advanced ICU care with
anesthesiology, and full-time endoscopy services, have been
recognized to be important for patient safety and to enable high-
quality surgical management. Clearly, surgical knowledge and
skills are crucial for obtaining good treatment outcomes; however,
the availability of general competence and mutual capacity at a
given hospital should be recognized in this context. A recent
nationwide study from Sweden demonstrated that university
hospitals had consistently good results compared with non-
teaching hospitals, independent of the annual volume. The lowest
“cut-off” per year was suggested to be 6 pancreatic procedures [17].
Here, we review the indications and outcomes of pancreatic
surgery over a period of more than 25 years. We also discuss the
development of a community-based hospital practice in a univer-
sity hospital for a well-deﬁned Norwegian population.
2. Materials and methods
2.1. Study population
Stavanger University Hospital (SUH) is currently the 4th largest
hospital in Norway and belongs to the governmental heath care
system. This system covers nearly all in-hospital medical care and is
based on a universal health coverage system [18]. Therefore, all
patients have equal access and rights to health care.
2.2. Patient identiﬁcation and inclusion criteria
We searched the hospital's electronic patient administrative
system for all patients who underwent pancreatic procedures be-
tween 1986 and 2012. Diagnosis-related ICD codes in combination
with relevant surgical procedure codes (NCMP ¼ Norwegian Clas-
siﬁcation of Medical Procedures) were used to identify patients. We
included all patients who had any form of pancreas resection for
any indication. Patients were excluded if they underwent explor-
atory procedures (i.e., laparotomy or laparoscopy) with or without a
palliative bypass in the case of an inoperable tumor or any mini-
mally invasive, endoscopic or per-cutaneous procedures on the
pancreas or peri-pancreatic tissues if a surgical resection or
correction procedure was not performed.
2.3. The evolving hospital
The population of the catchment area has grown from approx-
imately 230,000 people in the mid-1980s to more than 350,000 at
present, with SUH as the only hospital for this population. The
hospital provides all surgical treatment for malignant and benign
gastrointestinal diseases, with the exception of a few cases (e.g.,
organ transplantation) [18]. The hospital evolved from a Central
Hospital, with an integrated clinical teaching program for medical
students since 1997, to become ofﬁcially a University Hospital in
2004, afﬁliated with the Medical Faculty at the University of Bergen
(UoB). Thus, important changes in clinical content and care during
this period have taken place, including improvements in radiology
services [continuously improved CT technology, MRI availability,
and around-the-clock interventional radiology services for the last
decade] as well as increased access to subspecialty gastrointestinal
radiological services. A specialized postoperative recovery service
with round-the-clock monitoring is available for all major surgery
patients, but also high-dependency ICU beds with ventilator sup-
port if necessary. The regular bed ward is staffed with personnel
who are dedicated to upper gastrointestinal and HPB (hepato-
pancreato-biliary) services. The clinical responsibility of HPB-
surgery in particular, including performing or assisting at alloperations, have been undertaken by one or two particular senior
consultant surgeons at any time period, although a number of
surgeons have contributed clinically.
Over the last decade, there has been an increasing emphasis on
multidisciplinary evaluations and clinical decision-making to
improve the surgical management of HPB patients, including pre-
operative examinations, operative care and perioperative man-
agement. Services from a dedicated gastrointestinal nutritionist,
and routine physical therapy postoperatively have been important
parts of this approach. Patients are allowed and encouraged to
consume food at will from POD 1 based on research from our
institution [19]. A somatostatin analogue (Sandostatin™;
100 mg  3 s.c.) has been routinely used for 7 days postoperatively
since the late 1990s. Abdominal drains have been routinely used
over the last ﬁfteen years. Drains are removed as early as possible,
usually on POD 2 or 3 after testing for amylase content. All patients
receive thromboembolic prophylaxis with low molecular weight
heparin (Enoxaparin, Klexane™ 40 mg s.c.) while under ward care.
Over the last decade, weekly formal multidisciplinary team
meetings (MDT) between surgeons, oncologists, and radiologists
who are clinically involved in caring for this particular group of
patients provide greater contact and consultation between fellow
physicians.
2.4. Time period deﬁnitions
For the analysis over time, we divided the study period into the
following 3 time intervals: early (1986e1995), middle (1996e2005)
and recent (2006e2012). The time periods are arbitrary regarding
the evolution of care; however, they reﬂect periods of consistent
change in the care process, and the most recent time period (7
years) incorporates themost updatedmultidisciplinary approach to
the diagnosis, staging and management of patients with pancreatic
disease.
2.5. Outcomes
We investigated changes in patient demographics, disease
spectrum and procedure volume over time in relation to the pro-
cess variables, such as perioperative variables (i.e., length of sur-
gery, blood loss, re-operation rate and length of stay) and short-
term mortality (30-day and 60-day mortality).
Demographic and clinical information, including operative
notes and pathology reports, were retrieved from the hospital
records.
Postoperative complications were classiﬁed according to
Clavien-Dindo [20], in which grades IIIeIV are serious complica-
tions that require intervention (grade IIIa or IIIb) and/or may cause
organ dysfunction (grade IVa or IVb), and grade V is deﬁned as
postoperative patient death.
2.6. Follow-up
An individual 11-digit ID number is assigned to all citizens of our
country, and this enables complete follow-up until death or,
emigration from the country (in case further follow-up is not
possible). Follow-up information was collected from the hospital
records as well as from outpatient clinic notes from several de-
partments, including the oncology department, at the hospital. The
date of death was conﬁrmed using information from Statistics
Norway. The civil data on patients in the electronic patient journal
system at the hospital are updated from the National Population
Registry. These data include the place of residence and living status
(whether the person is alive or deceased).
Table 1
Characteristics of the 219 patients.
Age, median (range), yrs 64 (17e87)
Gender
Male 118 (53.9%)
Female 101 (46.1%)
ASA
I 22 (10.0%)
II 107 (48.9%)
III 87 (39.7%)
IV 3 (1.4%)
Type of surgery
PDa 150 (68.5%)
Dist. resection 55 (25.1%)
Tot. pancreatectomy 1 (0.5%)
Enucleation 5 (2.3%)
Otherb 8 (3.7%)
Final diagnosis
Ductal adenocarcinoma 66 (30.1%)
Ampulla Vaterii adenocarcinoma 26 (11.9%)
Distal cholangiocarcinoma 16 (7.3%)
NETs 15 (6.8%)
IPMN 14 (6.4%)
Duodenal adenocarcinoma 3 (1.4%)
Malignant overgrowth from
other cancer (i.e., gastric or colon)
21 (9.6%)
Cystic neoplasm 14 (6.4%)
Autoimmune pancreatitis 26 (11.9%)
Trauma 4 (1.8%)
Benign, other 10 (6.6%)
a PD ¼ pancreatoduodenectomy.
b Includes various procedures, such as a Beger procedure.
J.A. Søreide et al. / International Journal of Surgery 32 (2016) 116e1221182.7. Ethics
The Hospital Review Board approved the study as a quality
assurance project (REC# ID 164/2011) according to the general
guidelines provided by the Regional Ethics Committee.
2.8. Statistics
The statistical calculations were performed using IBM SPSS 22
for Mac (Chicago, IL). Assuming a non-normal distribution of vari-
ables, we applied non-parametric tests for the analyses. All the tests
were 2-sided, and a P-value <0.050 was considered statistically
signiﬁcant.
3. Results
3.1. Hospital volume
As shown in Fig. 1, the annual number of pancreas resections
was low during the ﬁrst 10 years of the study period, but increased
signiﬁcantly with time. Almost half (43.4%) of the operations were
performed during the most recent time period (2006e2012).
3.2. Patients
A total of 219 patients, including 118 (53.8%) males, with a
median age of 64 (range, 17e87) years received surgical treatment
of the pancreas for various conditions. The median age of the pa-
tients remained fairly stable during the study period. The patient
characteristics are displayed in Table 1. The distribution between
genders was nearly equal, and themajority of the patients (n¼ 194;
88.9%) had an ASA class of 2 or 3.
3.3. Indications
A pancreatic tumor, as determined by pre-operative imaging,
was the indication for surgery in 169 (77.2%) of the operations. The
remaining procedures were performed on 25 (11.4%) patients for
different conditions. Most conditions were usually related to a
previous event of acute or chronic pancreatitis. Notably, 20 (9.6%) of
the resections, including 4 pancreatoduodenectomy (PD) opera-
tions, were performed for loco-regional pancreatic involvement by
a malignant tumor in a neighboring organ (commonly gastricFig. 1. Annual number of pancreas resections. Increasing number of pancreas re-
sections performed in males and females during the study period of 27 years.cancer). Very rarely (4; 1.8%), trauma prompted a pancreatic
resection, and no Whipple procedures were performed for trauma.3.4. Operations
Pancreas head resection (PD) was most commonly performed
(150; 68.5%), and pylorus-preserving pancreatoduodenectomy
(PPPD) was performed in 120 (80%) of these patients; PPPD has
been used more frequently in recent years. Distal pancreas resec-
tion was performed in 55 (25.1%) of the patients, with splenectomy
accounting for 42/55 (76.4%) of these procedures. Enucleation of a
benign tumor (e.g., insulinoma) was performed in 5 (2.3%) patients;
this procedure was laparoscopically completed in 2 patients. Total
pancreatectomy for IPMN (intraductal papillary mucinous
neoplasm) was performed in 1 patient, and 8 (3.7%) patients un-
derwent various surgical procedures after pancreatitis, including 1
Beger procedure for disabling chronic pancreatitis. The patterns of
operations that were performed within the 3 time periods are
depicted in Fig. 2. Of note, no vascular resections (i.e., resections of
the portal or superior mesentery vein) were performed until the
most recent time period (2006e2012), during which 10 (9.5%) such
resections were performed, including 1 with graft replacement and
9 with primary anastomosis or a patch.
The median duration of the operations was 290 min (median for
PD, 310 min; median for distal pancreas resection, 210 min), and
there was a wide range in the duration (90e780 min). No signiﬁ-
cant change or reduction in the operative timewas observed during
the study period.
The estimated median perioperative blood loss for all the pa-
tients, including the trauma patients, was 950 ml (range,
20e9000 ml; interquartile range (IQR), 575e1500). More specif-
ically, we compared the change in blood loss over time for patients
who underwent a PD and observed a signiﬁcant reduction in the
median blood loss from 1250 ml in the ﬁrst period to 800 ml in the
most recent period (p < 0.001).
Fig. 2. Type of pancreas surgery by time periods. An increasing number of pan-
creaticoduodenectomies have been done during the study period. Of note, the last time
period is 7 years.
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3.5.1. Length of stay (LOS)
During the study period, the postoperative LOS decreased from a
median of 19 (range, 4e115) days in the ﬁrst decade to a median of
12 (range,1e124) days in themost recent time period (p < 0.001). A
similar reduction was observed in patients who underwent a PD
(n ¼ 130) for a suspected pancreatic tumor, with a median LOS of
19(IQR 13e31) days in the ﬁrst study period, and 12(IQR 10e22)
days in the most recent study period (p ¼ 0.002).Table 2
Postoperative complications according to time periods.
Complications Time period
1986e1995 1996e2005 2006e2012
(N ¼ 35) (%)* (N ¼ 89) (%)* (N ¼ 95) (%)*
Anastomose leak 1 (2.9) 8 (9.0) 2 (2.1)
Pancreas ﬁstula 1 (2.9) 3 (3.4) 4 (4.2)
Hemorrhage 5 (14.3) 9 (10.1) 4 (4.2)
Intrabd. abscess 2 (5.8) 4 (4.5) 10 (10.5)
Ileus/retension 1 (2.9) 2 (2.3) 4 (4.2)
Cardio-pulmonary 2 (5.8) 1 (1.1) 4 (4.2)
Infection 1 (2.9) 2 (2.3) 7 (7.4)
Sepsis, MOF 3 (8.6) 3 (3.4) 2 (2.1)
N ¼ number of pancreas resections done during the time period.
* percent within the time period.
MOF ¼ multi organ failure.3.5.2. Use of intensive care resources
During the ﬁrst decade, 32 (91.4%) of the 35 patients were
admitted to the ICU. In contrast, 12 (12.6%) of the 95 patients who
underwent an operation during the most recent 7-year time period
were admitted to the ICU (p < 0.001). The length of stay in the ICU
decreased signiﬁcantly from a median of 3 (range, 0e35) days in
the early decade to a median of 0 (range, 0e22) days in the most
recent time period (p< 0.001). A similar signiﬁcant reduction in ICU
stay, from a median of 3 to 0 days, was observed for the patients
(n ¼ 169) who were surgically treated for suspected pancreatic
tumors (p < 0.001).
Moreover, the same trend was observed in patients who un-
derwent a PD (n ¼ 130) for a suspected pancreatic tumor. Among
patients admitted to the ICU, the length of stay decreased from a
median of 4 (range, 1e35) days in the ﬁrst decade to a median of 3
(range,1e22) days in the second decade and to 2 (range,1e22) days
for the most recent time period (p ¼ 0.043). Respiratory support
followed the same trend and decreased signiﬁcantly. These obser-
vations were independent of the inclusion of the total study pop-
ulation (n ¼ 219) and of the restriction of the comparisons to
patients whowere surgically treated for a pancreas tumor (n¼ 169)
or to those who underwent a PD (n ¼ 130) for a pancreas head
tumor identiﬁed by imaging. Speciﬁcally, for patients who weresurgically treated for a recognized pancreas tumor (n ¼ 169), the
percentage of patients on postoperative ventilation decreased from
26.7% (8/30) in the ﬁrst decade to 20.0% (10/50) in the second
decade, with a further decrease to 5.9% (5/85) in the most recent
time period (p ¼ 0.006). For the patients in need of postoperative
ventilation, the median respirator time decreased from 3 days in
the ﬁrst decade to 1 day in the most recent time period (p ¼ 0.192).
3.5.3. Complications
Complications classiﬁed according to Clavien-Dindo as grade III
or higher were encountered in 71 patients (32.4%). Infectious
complications, including intra-abdominal abscess, postoperative
hemorrhage, anastomotic leakage and postoperative pancreatic
ﬁstula, were most frequently encountered in patients with severe
complications. As shown in Table 2, the pattern of complications
were very much the same for the three time periods. While the
proportion of severe complications gradually declined from 45.7%
in the ﬁrst time period to 29.5% in the recent time period, a sta-
tistical signiﬁcance was not achieved (p ¼ 0.322). However, the re-
operation rate decreased signiﬁcantly during the same time periods
from 37.1% (13/35) to 19.1% (17/89) in the second decade, ultimately
achieving a re-operation rate of 8.4% (8/95) in the last time period
(p < 0.001). Of the patients who died during the postoperative
course, re-operations were performed in 23 (82.1%) of the patients
with grade IIIb complications, all of the patients with grade IVa
(n ¼ 5) and grade IVb (n ¼ 2) complications, and 8 (53.3%) of the 15
patients with grade V complications.
3.5.4. Mortality
The overall 30-day postoperative mortality was 6.8% for all pa-
tients. As shown in Table 3, the overall 30-day mortality decreased
during the study period without reaching statistical signiﬁcance. In
contrast, the overall 60-day mortality signiﬁcantly decreased over
time (p ¼ 0.031).
Among the patients who were surgically treated for a suspected
pancreatic tumor (n ¼ 169) and those with a suspected tumor who
underwent a PD (n ¼ 130), both the 30-day and 60-day post-
operative mortality decreased signiﬁcantly over time (Table 2).
From 1996 to present, our postoperative 30-daymortality after a PD
has varied from 1.9 to 4.2%. The 60-day mortality has been between
5.6 and 7.4%.
4. Discussion
We found that improved perioperative care and increasing
operative volume were signiﬁcantly associated with better out-
comes based on several performance metrics as well as with
Table 3
Postoperative mortality according to time period and patient group.
1986e1995 (n ¼ 35) 1996e2005 (n ¼ 89) 2006e2012 (n ¼ 95)
All
resections
Resections for
suspected tumors
Pancreas head
resections (PD)
All
resections
Resections for
suspected tumors
Pancreas head
resections (PD)
All
resections
Resections for
suspected tumors
Pancreas head
resections (PD)
n ¼ 35 n ¼ 31 n ¼ 26 n ¼ 89 n ¼ 51 n ¼ 53 n ¼ 95 n ¼ 86 n ¼ 71
30-d mortality (%)a 14.3 16.1 15.4 4.5 2.0 1.9 6.3 3.5 4.2
60-d mortality (%)b 23.1 22.6 20.0 3.8 3.9 5.6 5.6 4.7 7.4
a Comparisons of 30-d postoperative mortality by time period: all resections, p ¼ 0.146; resections for suspected tumors, p ¼ 0.012; pancreas head resections, p ¼ 0.036.
b Comparisons of 60-d postoperative mortality by time period: all resections, p ¼ 0.031; resections for suspected tumors, p ¼ 0.003; pancreas head resections, p ¼ 0.007.
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to both higher volume but also a more focused perioperative
management and management care-bundles in a university hos-
pital setting, which has evolved over time and across several dis-
ciplines. While the effect of each is hard to measure, we
acknowledge that ‘the sum is greater than its parts’, and thus this is
reﬂected in improved overall outcomes.
In agreement with previous reports [2,10,21e23], we observed
that the number of pancreas resections increased and the periop-
erative mortality decreased during the study period. The post-
operative 30-day mortality (15%) for pancreas resections in the
early period was high but was in agreement with the ﬁgures re-
ported by others from the same period [24,25]. More importantly,
the consistently low postoperative mortality of 1.9e4.2% during the
most recent decade corresponds with data from other updated
series [22,25e27]. This applies to both patients with general
pancreas resections as well as those who underwent a PD. Addi-
tionally, this holds true for 60-day postoperative mortality. There-
fore, an improved 30-day mortality cannot be explained solely by
the enhanced ability to keep patients alive longer (i.e., more than 30
days) due to improved ICU care. Moreover, the decrease in peri-
operative blood loss, shorter postoperative hospital stay, and
minimal and continuously decreasing use of ICU resources indicate
an appropriate standard of care for this group of patients in our
hospital. A clinically important, yet not statistically signiﬁcant,
reduction in the incidence of severe postoperative complications
(i.e., patients with complications of Clavien-Dindo grade III or
higher) during the study period further illustrates this pattern of
improvements. Furthermore, the statistically signiﬁcant reduction
in re-operation rate during the entire study period, with only 8.4%
re-operations during the most recent time period (2006e2012),
emphasizes the change in the management of complications that
has occurred during recent years.
The current study assessed a series of pancreas resections that
were prompted by several different indications to reﬂect the sur-
gical approach for pancreatic disease in a well-deﬁned Norwegian
population. Therefore, the population per se (or surgical spectrum)
may not be immediately comparable with institutions that have a
tertiary referral proﬁle or specialized function for speciﬁc surgical
services. The reported epidemiology and incidence of peri-
pancreatic malignancies is in the range of that for other Western
countries; however, Norway has a lower incidence of acute and
chronic pancreatitis compared with the UK or continental Europe
[28,29]. Therefore, variations in the disease etiology between re-
gions may also be reﬂected in the spectrum of procedures that are
performed.
The observed improvements in several outcome measures (i.e.,
blood loss, ICU use, need for ventilation, and length of stay) can be
somewhat explained by the improved knowledge and skills of all
the professionals involved in the care of this particular group of
patients. Additionally, changing policies (e.g., improved surgical
techniques with an emphasis on meticulous dissection, routines forpostoperative pain management, criteria for referral to ICU, and
routine use of drains and nasogastric tubes) may have also
contributed to the improved outcome pattern. In this retrospective
study, we were unable to provide reliable details for every patient;
however, our approach to perioperative care has been guided by
making care easy according to the principles of enhanced recovery
[30].
An inverse relationship between the postoperative mortality
among patients surgically treated with complex procedures and
hospital volume has been investigated and extensively evaluated in
recent years [5,13,15,22]. This is also relevant for gastrointestinal
surgery, including pancreas resections [2,4,14,24,25,31e34]. As a
result, many countries have centralized the performance of certain
complex procedures in an attempt to improve the surgical care and
outcomes after such procedures [3,35e38]. Hospital volume is a
simple measure that may be associated with improved patient
outcomes; however, volume may not be the sole outcome deter-
minant [17,31,34,39,40]. In addition to an increased number of
operations at many institutions, several other changes have taken
place in the management of pancreatic cancer patients over recent
decades [30,41]. Imaging, pre-operative evaluation, and perioper-
ative care have improved, as has our ability to select patients for
complex surgery [23,41]. However, challenges remain as to show
whether treatments goals have been achieved by the introduction
of clinical measures and changes of care [42], and to deﬁne exactly
which factors are of importance or which decisions are needed to
arrive at an appropriate or optimal level of care [17,33,34,43e45].
The population-based design of our study is one of its many
strengths.
The hospital is the only institution that offers surgical treatment
for a geographically well-deﬁned region. The government runs the
health care system, and every citizen has access to the same level of
care. A patient selection bias due to different referral policies (as
can be encountered in many tertiary centers) is unlikely. The mix of
cases in our study population likely reﬂects the general population.
Additionally, long-distance patients, selection due to a lack of
health care insurance, or various other non-medical reasons for
biases are unlikely to have distorted the outcome interpretation
[9,40]. However, some limitations should be addressed. The retro-
spective study design makes it difﬁcult to provide reliable detailed
data on some clinical aspects of interest (i.e., the true frequency and
classiﬁcation of postoperative pancreas ﬁstula as well as delayed
gastric emptying). Moreover, during an extended study period of
nearly 3 decades, there have been numerous changes in imaging,
surgical techniques, adjuncts (i.e., the perioperative use of so-
matostatin receptor analogues and antibiotic prophylaxis), and
general routines in peri- and postoperative care [19] (including the
recent implementation of the elements of an enhanced recovery
policy [30]). Therefore, when improved outcomes are discussed,
multiple factors should be entertained to explain these changes.
Surgical knowledge, individual skills and experience are all
important. However, attention should be paid to several other
J.A. Søreide et al. / International Journal of Surgery 32 (2016) 116e122 121aspects, including perioperative care, the availability of the ICU, and
24/7 access to imaging and interventional radiology, when
specialized units for pancreas surgery are deﬁned [10,12,25,32,46].
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